Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player
Open Access
- 18 May 2020
- journal article
- review article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (4), 1488-1501
- https://doi.org/10.1002/ehf2.12728
Abstract
Heart failure is a growing health issue as a negative consequence of improved survival upon myocardial infarction, unhealthy lifestyle, and the ageing of our population. The large and complex pathology underlying heart failure makes diagnosis and especially treatment very difficult. There is an urgent demand for discriminative biomarkers to aid disease management of heart failure. Studying cellular pathways and pathophysiological mechanisms contributing to disease initiation and progression is crucial for understanding the disease process and will aid to identification of novel biomarkers and potential therapeutic targets. Growth differentiation factor 15 (GDF15) is a proven valuable biomarker for different pathologies, including cancer, type 2 diabetes, and cardiovascular diseases. Although the prognostic value of GDF15 in heart failure is robust, the biological function of GDF15 in adverse cardiac remodelling is not fully understood. GDF15 is a distant member of the transforming growth factor‐β family and involved in various biological processes including inflammation, cell cycle, and apoptosis. However, more research is suggesting a role in fibrosis, hypertrophy, and endothelial dysfunction. As GDF15 is a pleiotropic protein, elucidating the exact role of GDF15 in complex disease processes has proven to be a challenge. In this review, we provide an overview of the role GDF15 plays in various intracellular and extracellular processes underlying heart failure, and we touch upon crucial points that need consideration before GDF15 can be integrated as a biomarker in standard care or when considering GDF15 for therapeutic intervention.Keywords
Funding Information
- Dutch Heart Foundation (2013T084, CVON2014-11)
This publication has 159 references indexed in Scilit:
- Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHFEuropean Heart Journal, 2013
- Regulation of the Inflammatory Response in Cardiac RepairCirculation Research, 2012
- Aging-Associated Cardiovascular Changes and Their Relationship to Heart FailureHeart Failure Clinics, 2011
- Diabetes and the Risk of Heart FailureHeart Failure Clinics, 2011
- Inflammation-Induced Endothelial-to-Mesenchymal TransitionThe American Journal of Pathology, 2011
- In search of new therapeutic targets and strategies for heart failure: recent advances in basic scienceThe Lancet, 2011
- Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxisThe Journal of Experimental Medicine, 2011
- ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cellsMolecular Cancer Therapeutics, 2008
- Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathwaysMolecular Cancer Therapeutics, 2008
- Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmiaImmunology, 2006